2013 American Transplant Congress
Role of Foxp3 for Augmented Homeostatic Proliferation of Treg, The
Thomas E. Starzl Transplantation Institute, Pittsburgh, PA
CD4+Foxp3+ Tregs play a critical role in transplant tolerance. Foxp3 does not initiate thymic differentiation of natural Treg (nTreg), but is essential for later differentiation…2013 American Transplant Congress
Racial Differences and Income Disparities Are Associated with Worse Allograft and Death Outcomes in Kidney Transplant Recipients with Lupus Nephritis
Background: An analysis of income disparities and racial differences on renal transplant outcomes in recipients with lupus nephritis (LN) has not been reported.Methods: We identified…2013 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 24
HERAKLES Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Aim: To follow up (FU) on the evolution of renal function (RF) of immunosuppressive regimens with different calcineurin inhibitor (CNI) exposure at month (Mo)24 post…2013 American Transplant Congress
Pre-Transplant Immunologic Risk Assessment and Immune Monitoring of Kidney Transplant Recipients with Pre-Transplant Donor-Specific Anti-HLA Antibodies
Montefiore-Einstein Center for Transplantation, Bronx, NY
Background: We aimed to investigate the importance of pre-transplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-HLA antibodies (DSA) and immune monitoring of…2013 American Transplant Congress
Characterization of Human CD8+/TCR-/CD56dim/- Facilitating Cells In Vivo and In Vitro
We previously reported that bone marrow-derived CD8+/TCR- graft facilitating cells (FC) significantly enhance engraftment of HSC and prevent GVHD in mouse recipients. We have presently…2013 American Transplant Congress
Choice of Induction Therapy in Kidney Transplant: It’s Race Not PRA
Background: rATG and IL-2RA are the most common induction agents used for KTX. There is no consensus on choice of induction. The aim of this…2013 American Transplant Congress
Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: 5 Years Follow-Up of the ZEUS Trial
ZEUS Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Aim: To follow-up (FU) on renal function (RF), efficacy and safety after conversion to an Everolimus (EVE)/Enteric-Coated Mycophenolate Sodium (EC-MPS) regimen after cyclosporine A (CsA)…2013 American Transplant Congress
Outcome on Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 4 Year Data of the APOLLO Trial
APOLLO Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Objective: Assessment of renal function, safety and efficacy of an Everolimus (EVE) regimen after Calcineurin-Inhibitor (CNI) withdrawal in maintenance kidney allograft recipients.Methods: In an open-label,…2013 American Transplant Congress
Five-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT-EXT Study
Introduction: Long-term extension (LTE) results of BENEFIT-EXT demonstrated a consistent safety profile and sustained renal function improvement with belatacept vs CsA over time. Here we…2013 American Transplant Congress
Excellent Outcome Following Transplant Using Kidneys from Deceased Donors with Severe Acute Kidney Injury
Background: Our aim was to determine the outcome of transplanting kidneys from selected donors with severe AKI.Methods: We selected all patients receiving single organ deceased…
American Transplant Congress abstracts